Related Experiment Videos
Enhanced antiopiate activity in peptidomimetics of FMRFamide containing Z-2,3-methanomethionine
Abstract:
FMRFa is a molluscan peptide that has shown antiopiate activity in a number of mammalian test systems. The current study determined the antiopiate potency of FMRFa and two conformationally constrained peptidomimetics of FMRFa containing stereoisomers of Z-2,3-methanomethionine. Morphine abstinence signs were observed after varying doses (0.25-25.0 micrograms) of these substances were injected into the third ventricle of morphine-dependent rats. Although both peptidomimetics were far more potent than FMRFa itself, they bound with lower affinity than FMRFa to rat spinal cord receptors for the mammalian FMRFa-like peptide, NPFF.
Insights
The study investigated the antiopiate effects of FMRFamide (FMRFa) and its analogs in rats. Certain peptidomimetics showed greater potency in reducing morphine withdrawal symptoms than FMRFa itself.
Area of Science:
- Neuroscience
- Pharmacology
- Peptide research
Background:
- FMRFamide (FMRFa) is a peptide found in mollusks.
- FMRFa exhibits antiopiate activity in mammalian systems.
- Understanding FMRFa's interaction with mammalian opioid systems is crucial.
Purpose of the Study:
- To determine the antiopiate potency of FMRFa.
- To evaluate two conformationally constrained peptidomimetics of FMRFa.
- To compare the potency and receptor binding affinity of these compounds.
Main Methods:
- Morphine abstinence signs were induced in rats.
- FMRFa and its peptidomimetics were administered intracerebroventricularly.
- Doses ranged from 0.25 to 25.0 micrograms.
- Receptor binding affinity to rat spinal cord NPFF receptors was assessed.
Main Results:
- Both peptidomimetics demonstrated significantly higher antiopiate potency than FMRFa.
- The peptidomimetics exhibited lower binding affinity to rat spinal cord NPFF receptors compared to FMRFa.
- A dose-dependent reduction in morphine abstinence signs was observed.
Conclusions:
- Conformationally constrained peptidomimetics of FMRFa possess enhanced antiopiate potency.
- Potency and receptor binding affinity do not directly correlate for these compounds.
- These findings offer insights into the structure-activity relationships of FMRFa analogs in opioid modulation.